INSYS Therapeutics Slumps: INSY Falls 7% in Session – Tale of the Tape
INSYS Therapeutics, Inc. (INSY) saw a big move last session, as the company’s shares fell by nearly 7% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the recent trend for INSY as the stock is now up by over 14% since Feb 4.
On Mar 2, The Shuman Law Firm announced that it is investigating potential claims against certain officers and directors of INSYS Therapeutics.
The company has seen a flat track record when it comes to current year estimate revisions over the past few weeks (0 increases, 0 decreases), and the consensus for earnings hasn’t been in a trend either. This recent price action is discouraging, so make sure to keep a close watch on this firm in the near future, and especially on earnings estimates following the recent slump.
INSY currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked stock in the same sector is Abaxis, Inc. (ABAX), holding a Zacks Rank #1 (Strong Buy).